The Malaysian Reserve

Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD)

FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a ...